Stoke Therapeutics (NASDAQ: STOK) commits to $85.5M long-term HQ and lab lease

Rhea-AI Filing Summary

Stoke Therapeutics, Inc. entered into a new long-term lease for its corporate headquarters and laboratory space at 245 Fifth Avenue, Waltham, Massachusetts. The lease covers approximately 98,500 square feet and is scheduled to run through March 31, 2038, giving the company a stable base for its operations.

The agreement includes two options to extend the term by an additional five years each at then-prevailing market rates, which could keep the company in the facility well beyond 2038. Aggregate estimated base rent over the initial term is approximately $85.5 million, and the company will provide a $3 million security deposit via an irrevocable standby letter of credit that may be reduced over time under the lease terms.

Insights

Real estate and capital commitments analyst

Stoke locks in a sizable long-term HQ and lab lease through 2038.

Stoke Therapeutics has committed to a new headquarters and laboratory lease covering about 98,500 square feet in Waltham, Massachusetts, with an initial term ending on March 31, 2038. The aggregate estimated base rent over this period is $85.5 million, indicating a meaningful, long-duration operating commitment consistent with scaling lab and office needs.

The company will post a $3 million security deposit in the form of an irrevocable standby letter of credit, which the agreement allows to be reduced over time. The lease also provides two five-year extension options at then-prevailing market rates, giving flexibility to remain in place if the space continues to fit operational requirements.

From an investor perspective, this establishes long-term occupancy cost visibility but also adds a significant fixed lease obligation. Future disclosures in the period ended March 31, 2026 Form 10-Q, where the lease will be filed as an exhibit, may provide more detail on payment timing and accounting treatment.

8-K Event Classification

2 items: 1.01, 2.03

2 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement Financial

The company incurred a new significant debt or off-balance-sheet obligation.

Understanding 8-K Material Events →

false 0001623526 0001623526 2026-01-21 2026-01-21

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 21, 2026

Stoke Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-38938		47-1144582
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

45 Wiggins Ave
Bedford, Massachusetts		01730
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (781) 430-8200

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		STOK		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

On January 21, 2026, Stoke Therapeutics, Inc. (the “Company”) entered into a new lease for its corporate headquarters and laboratory with NWALP PHOP Property Owner LLC, located at 245 Fifth Avenue, Waltham, Massachusetts (the “Lease Agreement”), in order to expand its office and laboratory space. The Lease Agreement premises include approximately 98,500 square feet. The Lease Agreement will expire on March 31, 2038, and includes two options to further extend the Lease for an additional five years at the then-prevailing market rate. The aggregate estimated base rent payments due over the term of the Lease Agreement is approximately $85.5 million. The Company will pay a security deposit of $3 million in the form of an irrevocable standby letter of credit, which may be reduced over time in accordance with the terms of the Lease Agreement.

The foregoing description of the Lease is qualified in its entirety by reference to the Lease Agreement, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2026.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of Registrant.

The information set forth above in Item 1.01 of this Current Report on Form 8-K regarding the Lease Agreement is incorporated into this Item 2.03 by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						STOKE THERAPEUTICS, INC.
Date: January 27, 2026				By:		/s/ Thomas E. Leggett
						Thomas E. Leggett Chief Financial Officer

FAQ

What did Stoke Therapeutics (STOK) disclose in this 8-K?

Stoke Therapeutics disclosed that it entered into a new long-term lease agreement for its corporate headquarters and laboratory space in Waltham, Massachusetts.

How large is Stoke Therapeutics' new headquarters and lab space?

The new leased premises for Stoke Therapeutics include approximately 98,500 square feet of office and laboratory space.

What is the term of Stoke Therapeutics' new lease?

The lease for Stoke Therapeutics' new headquarters and laboratory is scheduled to expire on March 31, 2038, with two options to extend for an additional five years each at then-prevailing market rates.

What are the total base rent commitments under Stoke Therapeutics' new lease?

The aggregate estimated base rent payments due over the initial term of Stoke Therapeutics' new lease are approximately $85.5 million.

What security deposit is required under Stoke Therapeutics' new lease?

Stoke Therapeutics will provide a $3 million security deposit in the form of an irrevocable standby letter of credit, which may be reduced over time under the lease terms.

Will Stoke Therapeutics disclose the full lease agreement?

Yes. The company stated that a copy of the lease agreement will be filed as an exhibit to its Quarterly Report on Form 10-Q for the period ended March 31, 2026.